NCT03748836View on ClinicalTrials.gov

Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

ALPN-101

Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.

DRUG

Placebo

Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.

Trial Locations (1)

3004

Nucleus Network- Centre for Clinical Studies, Melbourne

Sponsors
All Listed Sponsors
collaborator

Clinical Network Services (CNS) Pty Ltd

INDUSTRY

lead

Alpine Immune Sciences, Inc.

INDUSTRY

NCT03748836 - Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety | Biotech Hunter | Biotech Hunter